SecBot SecBot
Biotech Drug Report Generated Aug 17, 2026

AXS-12

AXSM·Axsome Therapeutics, Inc.
NEUTRAL
Drug Impact Rating6/10
Trial phase
Filed/PDUFA (NDA accepted; Phase 3 completed)
Time to market
NDA is already under FDA review; a decision is due by May 1, 2027, with commercial launch in 2027 if approved, roughly 9 months to the binary.
Why 6/10
The single next hard, dated catalyst is the FDA PDUFA target action date of May 1, 2027 for the AXS-12 NDA in cataplexy/narcolepsy, a real binary ~8.5 months out on a meaningful pipeline asset, but at a company whose value is dominated by its approved AUVELITY/SUNOSI franchise, so it scores at the low end of the 6-7 band (not 8, since it is neither within 6 months nor the lead thesis-driver).
Actionable Insight NEUTRAL

Watch for FDA communications ahead of the May 1, 2027 PDUFA, e.g., any newly scheduled advisory committee, labeling discussions, or a potential priority-review/timing change, and treat AXS-12 approval as incremental upside on top of the AUVELITY (incl. Alzheimer's agitation) and SUNOSI commercial story rather than the stock's primary thesis. Near-term share moves are more likely tied to quarterly product sales and the Alzheimer's agitation launch than to AXS-12, since its binary is ~9 months out.

Price Chart

Loading chart...

Executive Summary

AXS-12 (reboxetine) is Axsome Therapeutics' repurposed oral treatment for cataplexy in narcolepsy. Its NDA was accepted by the FDA in July 2026 with a PDUFA target action date of May 1, 2027, and no advisory committee currently planned; it also holds Orphan Drug designation. AXS-12 is a genuine dated binary for AXSM in ~9 months, but the stock's main value drivers remain the approved products (AUVELITY and SUNOSI drove $218.4M of Q2 2026 net product revenue), making AXS-12 a meaningful but secondary catalyst, hence a neutral-to-cautiously-positive stance.

How It Works

AXS-12 is Axsome's formulation of reboxetine, an older medicine known as a selective norepinephrine reuptake inhibitor (NRI), it raises norepinephrine levels in the brain. In narcolepsy it is thought to help stabilize the abnormal REM-sleep muscle control that causes cataplexy (sudden, emotion-triggered muscle weakness) and to promote wakefulness. Reboxetine was previously marketed as an antidepressant in Europe (Edronax), so Axsome is repurposing a drug with a long human safety history rather than inventing a new chemical.

Trial Status

Phase 3 study (NCT05059223, ~90 patients) in narcolepsy/cataplexy completed March 2024 and the smaller Phase 2 CONCERT trial (NCT03881852, 21 patients) completed November 2019. NDA for cataplexy in narcolepsy was submitted May 2026, accepted for filing July 15, 2026, with a PDUFA target date of May 1, 2027; FDA does not currently plan an advisory committee meeting. AXS-12 holds FDA Orphan Drug designation for narcolepsy. Data were also presented at SLEEP 2026 (June 2026).

The Two-Sided Case

▲ Bull Case5
NDA accepted and FDA set a PDUFA target action date of May 1, 2027, with no advisory committee meeting currently planned, less regulatory-uncertainty risk.
AXS-12 has FDA Orphan Drug designation for narcolepsy, which can bring 7-year US exclusivity if approved.
Completed Phase 3 (NCT05059223, ~90 patients) and Phase 2 CONCERT (NCT03881852) plus decades of prior human use as an antidepressant reduce the 'new mechanism safety surprise' risk.
Street support is strong: AXSM consensus is strong-buy, 26 buy/strong-buy vs 2 hold and 0 sell, with a mean price target of $285.42 vs ~$216.35 (implied upside ~29.5%).
Q2 2026 institutional accumulation continued (Renaissance +59.5%, Morgan Stanley +68.7%, Dimensional +49.5% adds per 2026-Q2 13F changes), and the company already has commercial sales infrastructure for launch.
▼ Bear Case5
The PDUFA is ~8.5 months away (May 1, 2027), a distant binary with FDA refusal-to-file/CRL risk in between; the stock already ran up ~97.7% over 12 months.
Reboxetine is an old drug: it had generic competition and a mixed commercial/efficacy record as an antidepressant, so Axsome must differentiate it against entrenched narcolepsy treatments (e.g., oxybates, pitolisant) for a niche cataplexy population (context; not from web sources this session).
Insider selling: CEO Herriot Tabuteau sold ~$9.5M of stock on Aug 5, 2026 at $212.01 and ~$1.0M on Aug 6 at $213.95 (10b5-1 flagged).
Elevated short-sale flow: weighted short-volume ratio ~0.468 across 59 sessions, and several large holders trimmed or exited (UBS -72.2%, T. Rowe Price -51.2% per 2026-Q2 13F changes).
Financially, losses are widening (Q2 2026 net loss $51.3M, -$0.99 EPS) while SG&A surged ~60% to $208.1M, AXS-12 adds pipeline value but is not yet revenue and won't fix the burn.

Upcoming Catalysts

  • PDUFA target action date May 1, 2027 for AXS-12 NDA in cataplexy/narcolepsy (primary binary).
  • Any FDA advisory-committee announcement or CRL/warning in the review window before May 2027.
  • Quarterly earnings: AUVELITY/SUNOSI sales growth and Alzheimer's agitation launch trajectory (Q3 2026 report expected ~Nov 2026).
  • Potential commercial-launch prep/positioning updates for AXS-12 if FDA momentum builds.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Axsome Therapeutics, Inc. Press Release AXSM ·Originating report

Sources · 6

Hover a chip for the title
1 globenewswire.com2 globenewswire.com3 globenewswire.com4 sec.gov5 sec.gov6 sec.gov